Biomira heisst jetzt Oncothyreon !

Schön,mal wieder von dir zu hören,aber im vergleich zu dem ,was bei Genvec passiert ist,sind wir bei Onty noch relativ glimpflich davongekommen,die Trials sind ja zum glück nur vorrübergehend eingestellt,für dich wäre es eigentlich der optimale Zeitpunkt ,um bei Onty günstig einzusteigen,wie du es damals auf mein anraten hin auch schon vorhattest,aber ich glaube fast ,du hast mit Genta dein Vermögen verzockt,das scheissteil war schon bei 3 Cent (!!) und du wolltest ein fass aufmachen ,als Genta bei 1,20$ stand und du nicht verkaufst hast ......

Liebe Grüsse!

MFG
Chali  

SEATTLE, WA, June 17 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq:ONTY - News) today announced that Merck Serono, a division of Merck KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono, Inc., are resuming the worldwide clinical development program for Stimuvax(R) (BLP25 liposomal vaccine) in non-small cell lung cancer (NSCLC), including the Phase 3 START and INSPIRE trials. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees. The announcement follows a decision by the U.S. Food and Drug Administration (FDA) to partially lift the clinical hold it placed on the Investigational New Drug (IND) application for BLP25 liposome vaccine in March 2010 and allow the START trial to be resumed.

"Merck Serono worked constructively with the FDA and other health authorities to address the questions raised on the safety of BLP25 liposome vaccine in patients with NSCLC and, as a result, we can now resume our NSCLC clinical program," commented Dr. Bernhard Kirschbaum, Head of Global Research and Development of the Merck Serono division, Merck KGaA. "We have meanwhile received a number of regulatory approvals to restart in other countries and await approval in the remaining countries."

The Phase 3 STRIDE trial in advanced breast cancer remains on clinical hold by the FDA. Merck Serono announced that it will continue to work closely with the health authorities, including the FDA, to decide the next steps for this trial.

"Merck Serono remains highly committed to the development of BLP25 liposome vaccine and the well-being of the patients," said Dr. Wolfgang Wein, Executive Vice President, Oncology, Merck Serono. "We believe this therapeutic cancer vaccine has the potential to be a valuable addition to the future range of therapies for oncologists and their patients."

"The resumption of the BLP25 liposome vaccine clinical program is very good news for the oncology community and NSCLC patients. If the START and INSPIRE Phase III trials are successful, BLP25 liposome vaccine could play an important role in the treatment of these currently underserved patients," said Dr. Frances Shepherd, Director of the Medical Oncology Princess Margaret Hospital in Toronto, Ontario, Canada, and Coordinating Investigator of the START trial.

Merck Serono temporarily suspended its global clinical program for BLP25 liposome vaccine in all recruiting studies worldwide following the clinical hold put in place by the FDA in March 2010. The clinical hold followed a suspected unexpected serious adverse reaction of encephalitis, observed in a patient enrolled in an exploratory Phase 2 trial of BLP25 liposome vaccine in patients with multiple myeloma. To ensure the safety of the study subjects, the protocols in the NSCLC trials are being amended to add specific safety measures

MFG
Chali  

Könntest Deinen Thread mal wieder mit Leben füllen.

Von 1,50 bis 3,30 diesen Monat, da ist auch Mukke drin...

 

Also ich finde dass alles sehr gut aussieht..die Namen spielen da keine so grosse rolle  

steht heute bevor....

http://www.thestreet.com/_nasdaq/story/13169301/1/...EE&cm_ite=NA